<DOC>
	<DOC>NCT01547598</DOC>
	<brief_summary>This non-inferiority study will assess safety and efficacy of LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) versus DuoTrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on Travatan® Z (travoprost ophthalmic solution 0.004%) monotherapy.</brief_summary>
	<brief_title>Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Cloprostenol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Open angle glaucoma or ocular hypertension Best corrected visual acuity of 20/100 or better in both eyes Ocular surgery within 3 months, or anticipated ocular surgery within 12 weeks Previous treatment with LUMIGAN® RC or DuoTrav® History of LASIK, LASEK, RK or PRK in the study eye(s) Active ocular inflammation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>